News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Article

Pharmaceutical Executive

September 1, 2005

Pharmaceutical Executive

Pharmaceutical Executive-09-01-2005
Volume0
Issue 0

Legal: Jumping the Pond

Author(s):

Mark Herrmann,Richard Elks

Class actions threaten industries that deal with the public. If European lawmakers remove the restriction on class-action suits, consumers will be free to file cases. Pharma companies should take heed.

Class-action litigation threatens industries that deal with the public en masse. Automotive manufacturers, petrochemical companies—and certainly, pharmaceutical companies—are squarely in the cross hairs of product-liability and consumer-fraud class actions. Historically, class actions have been threats only in the United States. But today, these lawsuits pose a growing threat in Europe.

Mark Herrmann

Generally, litigation in Europe has been less threatening than US litigation for several reasons. First, there are fewer compensable damages in most European countries: Victims' medical expenses are frequently covered by nationalized healthcare, and employers or the government reimburses lost wages. Second, there are procedural restrictions in Europe on litigation: Discovery—disclosing vast quantities of documents and taking pre-trial testimony of witnesses—is limited, and contingent-fee agreements are unheard of. Third, European laws don't authorize class actions.

Richard Elks

If the last of those restrictions is removed, dangerous litigation could result. Many American pharma companies have been sued in the United States in consumer-fraud class actions. Plaintiffs in these cases claim that they overpaid for a drug that is allegedly ineffective or harmful. These cases do not seek reimbursement of medical expenses or lost wages; they seek only to aggregate a large number of small claims for plaintiffs who suffered no physical injuries. However, successful, consumer-fraud class actions could pose substantial risk to defendants. Indeed, the Class Action Fairness Act of 2005, recently enacted in the United States, was passed in large part to transfer these cases to federal courts, which are less likely to permit them to proceed.

Class actions in the United Kingdom and the European Union could become problematic as well. Although these jurisdictions do not typically award certain categories of damages, if European lawmakers remove the restriction on class-action lawsuits, plaintiffs will be free to file cases.

For example, so-called "group litigation" has existed in England for some time. In the late 1990s, the then-most senior English judge conducted a wide-ranging review of the litigation system and, in 1999, Parliament introduced the Civil Procedure Rules, which made group litigation quicker and easier to pursue.

Even in group litigation, individuals must institute their claims separately; one person cannot litigate on behalf of a class of claimants. Once related claims have been instituted, they can be conjoined either by the court's own motion or at the request of the parties. The court then analyzes one or two of the cases and uses those to resolve the common issues. That ruling binds all conjoined claims, but any award of damages is still adjudicated on a case-by-case basis. By permitting liability issues to be resolved on a common basis, these cases represent the embryonic form of mass torts.

Aggressive collective litigation is on the rise elsewhere. In Sweden, the Class Action Act, which went into effect on January 1, 2003, allows a private individual to institute proceedings on behalf of a group. Any individual in the group can opt into the action by notifying the court. The court's decision then binds everyone who has opted in. Although this mechanism has some limitations, it is still a far more potent threat than the individual lawsuits previously filed in Sweden.

Although Germany does not yet recognize class actions, plaintiffs' lawyers filed roughly 15,000 individual claims against Deutsche Telekom, Europe's biggest telephone company, when it suffered an 86-percent drop in share price. An extraordinary 754 German law firms were involved in the litigation. This is the type of coordination formerly seen only in the United States.

Proposals to permit other forms of aggregate litigation have been suggested in the Netherlands, France, and Italy. Although those proposals are in early stages of debate, pharma companies should pay heed. If aggregate litigation is permitted in Europe, clever plaintiffs may file cases that pose dangers despite the limited categories of available damages.

It is not yet clear whether class actions will take root in Europe. But if they do, beware: When class actions jump the pond, they may land on pharma.

Mark Herrmann is a partner at law firm Jones Day. He can be reached at mherrmann@jonesday.com

Richard Elks is an associate at law firm Jones Day. He can be reached at relks@jonesday.com

Articles in this issue

Missing the Mark(et)
Missing the Mark(et)
Washington Report: Crawford Steps Up
Washington Report: Crawford Steps Up
Sales Management: The X Factor
Sales Management: The X Factor
No Margin for Error
No Margin for Error
Global Report: Kids 'R' EU
Global Report: Kids 'R' EU
Thought Leader: (Eco)systemic Change
Thought Leader: (Eco)systemic Change
Track and Trace
Track and Trace
Missing the Mark(et)
Missing the Mark(et)
Marketing to Professionals: Doctor-Patient Communication
Marketing to Professionals: Doctor-Patient Communication
Legal: Jumping the Pond
Legal: Jumping the Pond
From the Editor: It Never Changes (Until It Does)
From the Editor: It Never Changes (Until It Does)

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Marcel Botha, 10XBeta
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Marcel Botha, 10XBeta
Related Content
Advertisement
Stock.adobe.com
August 1st 2025

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

Mike Hollan
Members of the industry believe the US should remain an innovation-friendly market.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia
August 1st 2025

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Don Tracy, Associate Editor
The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein cholesterol management.
Navigating Distrust: Pharma in the Age of Social Media
August 1st 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Stock.adobe.com
August 1st 2025

Report Says President Trump Pushed for Vinay Prasad’s Removal

Mike Hollan
Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
President Donald Trump
August 1st 2025

President Trump Issues Letters to 17 Major Pharma Companies Demanding Action on Most-Favored-Nation Order

Mike Hollan
The letter states that the companies have 60 days to meet the President's requirements.
Related Content
Advertisement
Stock.adobe.com
August 1st 2025

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

Mike Hollan
Members of the industry believe the US should remain an innovation-friendly market.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia
August 1st 2025

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Don Tracy, Associate Editor
The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein cholesterol management.
Navigating Distrust: Pharma in the Age of Social Media
August 1st 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Stock.adobe.com
August 1st 2025

Report Says President Trump Pushed for Vinay Prasad’s Removal

Mike Hollan
Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
President Donald Trump
August 1st 2025

President Trump Issues Letters to 17 Major Pharma Companies Demanding Action on Most-Favored-Nation Order

Mike Hollan
The letter states that the companies have 60 days to meet the President's requirements.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.